| Aus Gov - Health logo | AUSTRALIAN TECHNICAL ADVISORY GROUP ON IMMUNISATION (ATAGI) | **CLINICAL ADVICE** |
| --- | --- |
|  | **Issue date: 1 July 2020** |
|  |  |

ATAGI clinical advice ON CHANGES TO VACCINE RECOMMENDATIONS AND FUNDING for older non-indigEnous adults from 1 july 2020

It is important to read this statement in conjunction with The Australian Immunisation Handbook available at immunisationhandbook.health.gov.au and other related ATAGI statements on NIP schedule changes from 1 July 2020

## Overview of key changes to recommendations for the use of pneumococcal vaccines in non-indigenous adults from July 2020

* The recommended age for pneumococcal vaccination for non-Indigenous adults has been changed to **70 years** from 65 years of age. Refer to the [Australian Immunisation Handbook](https://immunisationhandbook.govcms.gov.au/).
* The vaccine now recommended for all non-Indigenous adults at ≥70 years of age is a single dose of 13vPCV (Prevenar 13*®*). This is funded under the NIP.
* The 23vPPV is now only recommended for individuals with risk conditions associated with an increased incidence of pneumococcal disease (Refer to the updated risk conditions list in the Australian Immunisation Handbook).

## Specific recommendations:

* All non-Indigenous adults should be given a dose of 13vPCV at ≥70 years of age regardless of receipt of 23vPPV previously.
* This single dose of 13vPCV is NIP-funded for those turning 70 years of age on or after 1 July 2020, regardless of whether the person has received 23vPPV previously. Those who are already 70 years of age or older on 1 July 2020 are also eligible for a single NIP-funded dose of 13vPCV, which can be given opportunistically at a suitable clinical encounter.
* If the individual has previously received doses of 23vPPV, the dose of 13vPCV should be given at least 12 months after their last 23vPPV dose.
* If the individual has already received a dose of 13vPCV (according to previous recommendations for people with category A risk conditions for pneumococcal disease), another dose of 13vPCV is not required.
* If the individual has underlying risk conditions for pneumococcal disease, 23vPPV is recommended in addition to the single dose of 13vPCV. The total number of 23vPPV doses received for the lifetime should not exceed two, including doses already received. These 23vPPV doses are NIP funded for individuals with certain conditions.(Refer to [ATAGI clinical advice on changes to vaccine recommendations and funding for people with risk conditions from 1 July 2020](https://health.gov.au/resources/publications/atagi-clinical-advice-on-vaccination-recommendations-for-people-with-risk-conditions-from-1-july-2020) further detailed information including the recommended intervals between vaccine doses).

## General recommendations:

* 13vPCV can be given at the same time as herpes zoster vaccine (Zostavax) for eligible individuals.
* 13vPCV can be given at the same time as any of the available influenza vaccines for eligible individuals.